Vivos Therapeutics, Inc.
$1.01
▲
3.12%
2026-04-21 10:12:00
www.vivos.com
NCM: VVOS
Explore Vivos Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$13.14 M
Current Price
$1.01
52W High / Low
$7.95 / $0.96
Stock P/E
—
Book Value
$0.31
Dividend Yield
—
ROCE
-108.39%
ROE
-3.35%
Face Value
—
EPS
$-1.77
Exp Qtr EPS
—
Sector
Healthcare
Industry
Medical Devices
Employees
262
Beta
6.9
Debt / Equity
493.6
Current Ratio
0.78
Quick Ratio
1.5
Forward P/E
-0.97
Price / Sales
0.83
Enterprise Value
$20.29 M
EV / EBITDA
-1.32
EV / Revenue
1.17
Rating
None
Target Price
$5
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | NeuroPace, Inc. | $16.53 | — | $545.07 M | — | -18.62% | -1.59% | $18.98 / $7.56 | $0.57 |
| 2. | AdaptHealth Corp. | $12.67 | — | $1.72 B | — | 5.17% | -4.25% | $12.87 / $7.11 | $11.46 |
| 3. | Sight Sciences, Inc. | $4.36 | — | $220.88 M | — | -35.58% | -50.74% | $9.24 / $2.4 | $1.2 |
| 4. | OrthoPediatrics Corp. | $16.65 | — | $420.89 M | — | -6.27% | -11.31% | $23.7 / $14.91 | $13.81 |
| 5. | Boston Scientific Corporation | $65.03 | 33.52 | $96.13 B | 0% | 10.39% | 12.45% | $109.5 / $60.59 | $16.34 |
| 6. | Aethlon Medical, Inc. | $2.39 | — | $3.67 M | — | -171.08% | -2.09% | $35.2 / $1.36 | $6.9 |
| 7. | CapsoVision, Inc. | $6.01 | — | $299.53 M | — | -185.75% | -1.85% | $15.37 / $3.43 | $0.28 |
Quarterly Results
Figures shown in M / B
| Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|
| Sales | 6.78 M | 3.82 M | 3.02 M | 3.7 M | 3.86 M |
| Operating Profit | -4.73 M | -4.87 M | -3.92 M | -2.81 M | -2.65 M |
| Net Profit | -5.4 M | -5.01 M | -3.86 M | -2.83 M | -2.62 M |
| EPS in Rs | -0.46 | -0.42 | -0.33 | -0.24 | -0.22 |
Profit & Loss
Figures shown in M / B
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Sales | 15.03 M | 13.8 M | 16.02 M | 16.89 M |
| Operating Profit | -11.17 M | -17.3 M | -25.03 M | -19.47 M |
| Net Profit | -11.14 M | -13.58 M | -23.84 M | -20.29 M |
| EPS in Rs | -0.94 | -1.15 | -2.02 | -1.72 |
Balance Sheet
Figures shown in M / B
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Total Assets | 15.28 M | 10.73 M | 13.72 M | 33.69 M |
| Total Liabilities | 7.33 M | 10.32 M | 8.92 M | 8.15 M |
| Equity | 7.95 M | 0.41 M | 4.8 M | 25.54 M |
| Current Assets | 7.47 M | 2.46 M | 5.42 M | 27.32 M |
| Current Liabilities | 4.98 M | 7.29 M | 6.81 M | 7.51 M |
Cash Flow
Last available yearly cash flow history
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Operating CF | -12.69 M | -11.95 M | -19.59 M | -15.73 M |
| Investing CF | -0.57 M | -0.85 M | -0.92 M | -2.61 M |
| Financing CF | 17.88 M | 10.92 M | 0 M | 24.17 M |
| Free CF | -13.26 M | -12.75 M | -20.51 M | -18.13 M |
| Capex | -0.57 M | -0.8 M | -0.92 M | -2.4 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 8.91% | -13.87% | -5.1% | — |
| Earnings Growth % | 18.02% | 43.04% | -17.53% | — |
| Profit Margin % | -74.09% | -98.42% | -148.81% | -120.15% |
| Operating Margin % | -74.32% | -125.32% | -156.21% | -115.32% |
| Gross Margin % | 60% | 59.93% | 62.52% | 74.65% |
| EBITDA Margin % | -70.45% | -120.82% | -152.03% | -115.73% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2023-10-27 | 1:0.04 |